Entebbe Cohort EVT

Section A – Demographics

Total unique participants

958

958

Sex

(n=952)

Female

Male

685 (72.0%)

267 (28.0%)

Age

(n=376)

Mean (SD)

39.5 (8.0)

Section B – ART Initiation

Date of ART initiation

(n=267)

Range

22 Jul 1999 – 27 Apr 2006

Section C – Clinical Events within 12 Months of ART

Clinical event within 12 months

(n=943)

Yes

No

537 (56.9%)  

406 (43.1%)  

Suspected immune-reconstitution disease (IRD)

(n=434)

Yes

No

23 (5.3%)   

411 (94.7%)

Section D – Toxicity within 12 Months of ART

Documented toxicity event

(n=624)

Yes

No

51 (8.2%)  

573 (91.8%)

Toxicity nature 1

(n=52)

Median (IQR)

16.99 (11.41; 52.07)

Toxicity grade 1

(n=26)

1

2

3

4

13 (50.0%)

2 (7.7%)

3 (11.5%)

8 (30.8%)

Toxicity nature 2

(n=10)

Median (IQR)

11.46 (11.41; 11.54)

Toxicity grade 3

(n=7)

1

2

3

4

3 (42.9%)

1 (14.3%)

2 (28.6%)

1 (14.3%)

Section E – ART Interruption within 12 Months

Drug interruption

(n=277)

Yes

No

23 (8.3%)  

 254 (91.7%)

Duration of interruption

(n=23)

Median [IQR]

3.0 [1; 7] months

Reason for interruption – 1st reason

(n=23)

No money

Side effects

TB treatment

Travelled

Other

14 (60.9%)  

5 (21.7%)  

2 (8.7%)  

1 (4.3%)  

1 (4.3%)

Reason for interruption – 2nd reason

(n=4)

Side effects

Travelled

Other

2 (50.0%)

1 (25.0%)

1 (25.0%)